Lisinopril

Generic Name: Lisinopril

Brand Names: Prinivil, Qbrelis, Zestoretic, Zestril

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₁N_₃O_₅

CAS Number: 76547-98-3

Unique Ingredient Identifier: 7Q3P4BS2FD

Background: Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.

Lisinopril was granted FDA approval on 29 December 1987.

Indication: Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.

Associated Conditions: Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine

Clinical Trials

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

Phase 4

Terminated

Conditions: Hypertension
Diabetes Mellitus, Type 2

Interventions: Drug: Carvedilol Controlled Release (CR)
Drug: lisinopril

First Posted Date: 2007-02-01

Last Posted Date: 2024-04-16

Lead Sponsor: University at Buffalo

Target Recruit Count: 14

Registration Number: NCT00430040

Locations: 🇺🇸
Diabetes - Endocrinology Center of Western New York, Buffalo, New York, United States

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: lisinopril
Drug: carvedilol controlled release formulation

First Posted Date: 2006-07-04

Last Posted Date: 2016-12-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 654

Registration Number: NCT00347360

Locations: 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States

The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes
Diabetic Retinopathy
Eye Diseases
Diabetes Complications

Interventions: Drug: Amlodipine
Drug: Lisinopril

First Posted Date: 2006-06-15

Last Posted Date: 2009-06-23

Lead Sponsor: University of Aarhus

Target Recruit Count: 25

Registration Number: NCT00337298

Locations: 🇩🇰
Aarhus university hospital, Aarhus, Denmark

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathy

First Posted Date: 2006-04-06

Last Posted Date: 2006-04-06

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 52

Registration Number: NCT00311870

Locations: 🇩🇰
Steno Diabetes Center, Gentofte, Denmark

HALT Progression of Polycystic Kidney Disease Study A

Phase 3

Completed

Conditions: Kidney, Polycystic

Interventions: Drug: Lisinopril
Drug: Placebo
Drug: Telmisartan
Other: Low Blood Pressure Control
Other: Standard Blood Pressure Control

First Posted Date: 2006-01-30

Last Posted Date: 2020-04-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 558

Registration Number: NCT00283686

Locations: 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸
Tufts University-New England Medical Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 4 locations

Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-10-18

Last Posted Date: 2011-11-23

Lead Sponsor: Novartis

Target Recruit Count: 1099

Registration Number: NCT00241124

VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-09-15

Last Posted Date: 2017-05-17

Lead Sponsor: Novartis

Target Recruit Count: 134

Registration Number: NCT00171067

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Antialbuminuric Effects of Valsartan and Lisinopril

Phase 4

Terminated

Conditions: Hypertension
Early Diabetic Nephropathy

First Posted Date: 2005-09-15

Last Posted Date: 2011-11-08

Lead Sponsor: Novartis

Target Recruit Count: 54

Registration Number: NCT00171600

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Antiproteinuric Effect of Valsartan and Lisinopril

Phase 4

Completed

Conditions: Hypertension
Diabetic Nephropathy

First Posted Date: 2005-09-15

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis

Target Recruit Count: 124

Registration Number: NCT00171574

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy